{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:22:05Z","timestamp":1761844925990,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.soc.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T23:22:30Z","timestamp":1529536950000},"page":"539-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Peritoneal Metastases from Malignant Mesothelioma"],"prefix":"10.1016","volume":"27","author":[{"given":"Claire Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"H. Richard","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.soc.2018.02.010_bib1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price","year":"2009","journal-title":"Crit Rev Toxicol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.010_bib2","first-page":"935","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"4","key":"10.1016\/j.soc.2018.02.010_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4149\/neo_2014_053","article-title":"Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma","volume":"61","author":"Kaya","year":"2014","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.soc.2018.02.010_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"10.1016\/j.soc.2018.02.010_bib5","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial","volume":"26","author":"Simon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.010_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.soc.2018.02.010_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1245\/s10434-006-9187-5","article-title":"Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma\u2013a prospective study of 70 consecutive cases","volume":"14","author":"Yan","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.010_bib8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2018.02.010_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/path.1700120212","article-title":"Malignant tumor arising from endothelium of peritoneum, and producing mucoid ascitic fluid","volume":"12","author":"Miller","year":"1908","journal-title":"J.Path.& Bact"},{"key":"10.1016\/j.soc.2018.02.010_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1097-0142(196001\/02)13:1<127::AID-CNCR2820130124>3.0.CO;2-6","article-title":"Malignant peritoneal mesotheliomas: a clinicopathological analysis of 12 fatal cases","volume":"13","author":"Winslow","year":"1960","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.010_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(19)33323-2","article-title":"Peritoneal mesothelioma","volume":"63","author":"Moertel","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.soc.2018.02.010_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0002-9343(80)90103-5","article-title":"Multimodality therapy for malignant mesothelioma based on a study of natural history","volume":"68","author":"Antman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.soc.2018.02.010_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.1983.1.6.386","article-title":"Peritoneal mesothelioma: natural history and response to chemotherapy","volume":"1","author":"Antman","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2018.02.010_bib14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM196503182721104","article-title":"Relation between exposure to asbestos and mesothelioma","volume":"272","author":"Selikoff","year":"1965","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2018.02.010_bib15","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2018.02.010_bib16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.1983.1.11.695","article-title":"Malignant mesothelioma following radiation exposure","volume":"1","author":"Antman","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.010_bib17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.soc.2018.02.010_bib18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/oem.51.12.804","article-title":"Malignant mesothelioma: attributable risk of asbestos exposure","volume":"51","author":"Spirtas","year":"1994","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.soc.2018.02.010_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","article-title":"BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma","volume":"13","author":"Alakus","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"15","key":"10.1016\/j.soc.2018.02.010_bib20","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.soc.2018.02.010_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.soc.2018.02.010_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/sonc.2002.30236","article-title":"Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience","volume":"29","author":"Sugarbaker","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.soc.2018.02.010_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/JCO.1988.6.1.147","article-title":"Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985","volume":"6","author":"Antman","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2018.02.010_bib24","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","article-title":"Current trends in the management of malignant peritoneal mesothelioma","volume":"21","author":"Miura","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.010_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/annonc\/mdp307","article-title":"Malignant peritoneal mesothelioma: a multicenter study on 81 cases","volume":"21","author":"Manzini Vde","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.soc.2018.02.010_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.soc.2018.02.010_bib27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAT.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"issue":"7","key":"10.1016\/j.soc.2018.02.010_bib28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/j.soc.2018.02.010_bib29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/PAS.0b013e318033e7a8","article-title":"h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary","volume":"31","author":"Comin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.soc.2018.02.010_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"issue":"9","key":"10.1016\/j.soc.2018.02.010_bib31","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A\u00a0novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.010_bib32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","article-title":"A\u00a0novel nomogram for peritoneal mesothelioma predicts survival","volume":"20","author":"Schaub","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.010_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2006.09.023","article-title":"Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: outcomes of an expanded access program","volume":"55","author":"Obasaju","year":"2007","journal-title":"Lung Cancer"},{"issue":"10026","key":"10.1016\/j.soc.2018.02.010_bib34","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.soc.2018.02.010_bib35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","article-title":"The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Deraco","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2018.02.010_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-institutional retrospective study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.soc.2018.02.010_bib37","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.soc.2018.02.010_bib38","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.soc.2018.02.010_bib39","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"36","key":"10.1016\/j.soc.2018.02.010_bib40","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2018.02.010_bib41","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1245\/s10434-017-5834-2","article-title":"Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"24","author":"Li","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.010_bib42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1245\/s10434-012-2236-3","article-title":"Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures","volume":"19","author":"Low","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2018.02.010_bib43","doi-asserted-by":"crossref","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","article-title":"MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma","volume":"9","author":"Kanteti","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.soc.2018.02.010_bib44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320718300206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320718300206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:02:44Z","timestamp":1760961764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320718300206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1055320718300206"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2018.02.010","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peritoneal Metastases from Malignant Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}